• HTA304 Subsequent Treatments and NICE Appraisals for DLBCL: A Review of Committee Discussions

    Dec 1, 2025, 00:00

  • MSR55 Clinically Informed, Cost-Sensitive Machine Learning for Predicting Hospital-Acquired Pressure Injuries: A Practical Approach Using Routinely Collected Data

    Dec 1, 2025, 00:00

  • CO209 Real-World Treatment Patterns and Outcomes in First-Line Small-Cell Lung Cancer (SCLC) in France

    Dec 1, 2025, 00:00

  • EE201 Cost-Effectiveness Analysis of GAAD Algorithm for Hepatocellular Carcinoma Surveillance of Cirrhotic Patients Using Italian Real-World Data

    Dec 1, 2025, 00:00

  • EE132 Clinical and Economic Perspectives on Influenza and COVID-19 Vaccine Combinations

    Dec 1, 2025, 00:00

  • HTA220 Life Years Generated for Relapsed/Refractory Mantle Cell Lymphoma Patients Managed on CAR-T in an England NHS Setting

    Dec 1, 2025, 00:00

  • CO187 Preventing Bleeds in Pediatric Patients With Hemophilia A: Which Factor Replacement Therapy Offers the Best Protection and at What Cost?

    Dec 1, 2025, 00:00

  • CO130 Health-Related Quality of Life (HRQoL) Impacts in Individuals With Hypophosphatasia (HPP): A Systematic Literature Review (SLR)

    Dec 1, 2025, 00:00

  • EE27 A Prevalence-Weighted ICER Approach With Scenario Analyses for HTA Without RCT Evidence

    Dec 1, 2025, 00:00

  • HTA111 Differential HTA Recommendations for Continuous Glucose Monitors (CGMs): A Global Comparative Review of HTA Focus, Challenges, and Solutions

    Dec 1, 2025, 00:00

  • EE373 Economic Evaluation of a Standardized Care Pathway for Nontraumatic Acute Abdominal Pain in the Emergency Department

    Dec 1, 2025, 00:00

  • HTA194 Impact of the Introduction of the NICE Severity Modifier on HTA Outcomes of Oncology and Non-oncology Orphan Drugs

    Dec 1, 2025, 00:00

  • Impact of Constrained Access to Primary Care on Health-Related Quality of Life

    Dec 1, 2025, 00:00

  • HTA120 Economic Assessments of Rare Disease Drugs in Fran Insights From CEESP Opinions Reviews

    Dec 1, 2025, 00:00

  • EE742 Unlocking the Value of RSV Adult Vaccination With Adjuvanted RSVpreF3 Vaccine in Germany: A Return on Investment Analysis Using an Integrated Actuarial-Macroeconomic Model

    Dec 1, 2025, 00:00

  • EE635 Real-World Cost-Utility of Faricimab vs. Current and Future Anti-VEGF Therapies in Patients With Neovascular Age-Related Macular Degeneration in Italy

    Dec 1, 2025, 00:00

  • HPR145 Navigating Implementation of the EU HTA Regulation for Medical Devices: Insights From National HTA Bodies Across Europe

    Dec 1, 2025, 00:00

  • EE294 Cost-Substitution and Hospital Diagnosis-Related Group (DRG) Performance Impact Analysis of Infliximab Biosimilar Adoption in Moderate-to-Severe Crohn's Disease Patients in China

    Dec 1, 2025, 00:00

  • PCR269 Why Are Patient-Reported Outcome Measure (PROM) Results Missing From Labels of Obesity Management Medications?

    Dec 1, 2025, 00:00

  • MSR156 NICE and CDA Assessment of Artificial Intelligence-Enabled Health Technologies: Analysis and Insights

    Dec 1, 2025, 00:00

  • EPH186 Premature Cancer-Related Morbidity and Mortality in Israel: Years Lived With Disability and Years of Life Lost Productivity Costs

    Dec 1, 2025, 00:00

  • MSR114 Generalizability of a Randomized Clinical Trial-Based Prediction Model in a Real-World Population

    Dec 1, 2025, 00:00

  • PCR191 Preferences for a Combination Influenza and COVID-19 Vaccine: Results From a Stated-Preference Survey With Consumers in the United States, United Kingdom, and Germany

    Dec 1, 2025, 00:00

  • HPR166 Public Spending on Medicines Between 2018 and 2026: Lessons for Designing a New Financing Model in Portugal

    Dec 1, 2025, 00:00

  • HTA346 Understanding the Impact of Equality and Equity Considerations on NICE Highly Specialized Technology (HST) Decision Making

    Dec 1, 2025, 00:00

  • CO146 Improving Colorectal Cancer Surgical Outcomes Through Audit and Feedback: Results From the Emilia Romagna ESCA Program

    Dec 1, 2025, 00:00

  • EE302 Cost-Utility Analysis of Iptacopan for Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated With C5 Inhibitor in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • EE138 Comparative Cost-Effectiveness Analysis of Isavuconazole vs. Liposomal Amphotericin B for the Treatment of Invasive Mucormycosis in Algerian Hospital Setting

    Dec 1, 2025, 00:00

  • CO218 Semaglutide Weight Outcomes Among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Real-World Setting

    Dec 1, 2025, 00:00

  • EE320 Deep Brain Stimulation: A Cost-Saving Treatment Option for Extreme Treatment-Refractory Obsessive-Compulsive Disorder in the UK?

    Dec 1, 2025, 00:00

  • MSR152 Natural History of Creutzfeldt-Jakob Disease: A Comparison of Manual vs. Manual Plus AI-Assisted Approaches in Literature Review

    Dec 1, 2025, 00:00

  • HSD65 Investing in Diagnosis: Health Economic Value of Early Obstructive Sleep Apnea Detection for Private Insurers in India

    Dec 1, 2025, 00:00

  • SA3 A Scoping Review of Resource Modeling in HTA Using Discrete Event Simulation

    Dec 1, 2025, 00:00

  • EE110 Budget Impact of Metyrapone for the Treatment of Cushing’s Syndrome in France

    Dec 1, 2025, 00:00

  • EE255 Cost-Effectiveness of I-CREATE: An Inpatient Intrinsic Capacity Risk Evaluation Towards Holistic Assessment and Targeted Management of Elderly in Acute Care

    Dec 1, 2025, 00:00

  • HPR22 Analysis of ATC Equivalent Group and Therapeutic Reference Code Distributions Based on Drug Price and Reimbursement Lists in Türkiye Between 2020 and 2025

    Dec 1, 2025, 00:00

  • CO245 The Mirage of Stability: Challenges of Predicting Disease Activity Over Time in Systemic Lupus Erythematosus (SLE)

    Dec 1, 2025, 00:00

  • EE508 Healthcare Resource Utilization (HCRU) Analysis in Newly Diagnosed Mantle Cell Lymphoma: Autologous Stem Cell Transplantation (ASCT) and (HCRU) Alleviation With Adoption of the TRIANGLE Ibrutinib Regimen Without (ASCT)

    Dec 1, 2025, 00:00

  • EE540 Impact of Proteinuria and Declining Kidney Function on the Healthcare Resource Utilization and Associated Costs of Patients With IgA Nephropathy: A Retrospective Analysis in the UK and Spain

    Dec 1, 2025, 00:00

  • MSR99 Evaluation of the Measurement Properties of the German LupusPRO™ for Swiss-German SLE Patients

    Dec 1, 2025, 00:00

  • MSR74 Development of Prioritization Criteria for Implementation and Further Development of HTA Methods: Results From SUSTAIN-HTA

    Dec 1, 2025, 00:00

  • PCR62 Development of the Adelphi Caregiver Experience Questionnaire© (ACARE): A Novel Tool Designed to Measure and Understand the Burden and Quality of Life Impacts of the Caregiver Role

    Dec 1, 2025, 00:00

  • RWD94 Healthcare Resource Utilization Associated With Acute Pancreatitis in Patients With Familial Chylomicronemia Syndrome Treated With Olezarsen: A Post Hoc Analysis of Balance Study Data

    Dec 1, 2025, 00:00

  • EPH245 The Incidence Mortality and Survival of Malignant Chondrosarcoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • HPR123 Innovation in Off-Patent Competitive Environment: Key Learnings From Successes and Failures

    Dec 1, 2025, 00:00

  • HTA17 Acceptability of Early Endpoints in NICE Appraisals for Adjuvant and Neoadjuvant Oncology Therapies

    Dec 1, 2025, 00:00

  • HTA372 Will Patient Input Shape EU-Level HTA Assessments? HTA Representative Perspectives on the EU HTA Regulation

    Dec 1, 2025, 00:00

  • P55 Choosing Appropriate Population-Adjusted Indirect Comparison Methods for Health Technology Assessment: A Simulation Study on the Impact of Effect Modifiers Baseline Imbalances and Sample Size

    Dec 1, 2025, 00:00

  • EE391 Economic Evaluations of First-Line Non-Small Cell Lung Cancer Therapies: A Systematic Review With Focus on PD-L1 Subgroups

    Dec 1, 2025, 00:00

  • EE385 Economic Evaluation of Surfactant Therapy for Neonatal Respiratory Distress Syndrome: 5-Year Real-World Evidence on Poractant Alfa vs. Beractant From the IMSS Perspective in Mexico

    Dec 1, 2025, 00:00

  • MSR201 The Role of Qualitative Research in Randomized Controlled Trials Involving Drugs and Medical Devices: A Systematic Mapping Review

    Dec 1, 2025, 00:00

  • HSD33 Differential Impact of Type 1 and Type 2 Diabetes on Families: A UK Cross-Sectional Study Using FROM-16

    Dec 1, 2025, 00:00

  • PCR215 Shared Decision Making in Inflammatory Bowel Disease: An Observational Study Combining Patient Physician and Observer Perspectives

    Dec 1, 2025, 00:00

  • HPR46 Comparative Analysis of Access and Pricing Timelines for Innovative Medicines in the US, Europe, and Japan Pre- and Post-Pricing Reform 2021-2025

    Dec 1, 2025, 00:00

  • EE23 A Model-Based Estimation of Productivity-Adjusted Life Years Due to Depression in Germany

    Dec 1, 2025, 00:00

  • MSR187 Simulation-Guided Trial Planning of a Cluster Randomized Trial With Probabilistic Covariate-Constrained Randomization for Vaccine Coverage

    Dec 1, 2025, 00:00

  • EPH56 Delta Price Cost-Effectiveness Analysis of PCV21 vs. PCV20 Use in Adults Aged ≥18 Years in Austria

    Dec 1, 2025, 00:00

  • PCR238 The PAVING II Interview Study: Assessing Evolving Patient Preferences Regarding Gene Therapy for Hemophilia Patients

    Dec 1, 2025, 00:00

  • CO151 Indirect Treatment Comparisons in Health Technology Assessment Submissions: A Review and Critique of Best Practice

    Dec 1, 2025, 00:00

  • HPR225 Trends in EMA-Approved New Medicines 2015-2024: New Mechanisms of Action and Regulatory Shifts

    Dec 1, 2025, 00:00

  • EE309 Cost-Utility Analysis of the AlloMap® Test for the Monitoring of Patients After Heart Transplantation: Economic Evaluation Alongside the CUPIDON Trial

    Dec 1, 2025, 00:00

  • SA89 Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in the UK

    Dec 1, 2025, 00:00

  • EE148 Components of the Direct Cost of Topical Treatment for Chronic Wounds in Adults and Elderly: A Systematic Review

    Dec 1, 2025, 00:00

  • EE594 NCFBE Hospitalizations Costs Across Different Healthcare Systems: Insights From England and France in 2022 Using PMSI and HES Databases

    Dec 1, 2025, 00:00

  • OP13 Knowledge of Natural Contraception and Its Effect on the Relationship: Mobile Application

    Dec 1, 2025, 00:00

  • HTA69 Challenges at the Interface Between EUHTA (JCA) and National HTA in Germany (AMNOG): Expected Limitations to Synergy Effects and Implications for AMNOG Dossier Preparation

    Dec 1, 2025, 00:00

  • MSR144 Measuring Health-Related Quality of Life and Food Insecurity in the General Population in Lebanon During the Third Worst Socioeconomic Crisis in History

    Dec 1, 2025, 00:00

  • EE389 Economic Evaluation of the Breast Thermal Activity Indicator Plus Clinical Breast Examination

    Dec 1, 2025, 00:00

  • CO149 Increased Functional Impairment Associated With Generalized Anxiety Disorder (GAD): Findings From a Systematic Literature Review

    Dec 1, 2025, 00:00

  • HTA177 Healthstate Utilities for Hormone Receptor-Positive (HR+) Human Epidermal Growth Factor-Receptor 2 Negative (HER2-) Breast Cancer

    Dec 1, 2025, 00:00

  • EE188 Cost Trends for Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Management in Relapsed/Refractory Large B-cell Lymphoma (R/R LBCL) Treatment With Axicabtagene Ciloleucel (Axi-cel) in ...

    Dec 1, 2025, 00:00

  • HTA2 A Comparative Analysis of Reimbursement Decisions for Targeted Therapies and Immunotherapies in NSCLC Across EU HTA Bodies

    Dec 1, 2025, 00:00

  • HPR129 Introducing an Access-Based Pricing Model to Determine Prices and Inform Price Negotiations for Newly Authorized Medicinal Products

    Dec 1, 2025, 00:00

  • EE676 Surviving but Not Earning? Long-term Income Trajectories in Working-Age mIDH Glioma Patients: Stratification by Radiotherapy/Chemotherapy Exposure

    Dec 1, 2025, 00:00

  • EPH158 Literature Review on the Economic Impact of Maternal Fetal Infections

    Dec 1, 2025, 00:00

  • HTA258 Nutrieconomics: Concept and Expert Consensus on Health Technology Assessment of Nutritional Interventions in Brazil

    Dec 1, 2025, 00:00

  • EE149 Comprehensive Uncertainty Assessment in Economic Evaluations of AI-Based Health Technologies: Pitfalls and Recommendations

    Dec 1, 2025, 00:00

  • EPH122 Healthcare Resource Use in Uncontrolled Hypertension: An Observational Study in England Using Electronic Health Records

    Dec 1, 2025, 00:00

  • EE232 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) Among High-Risk Adults in Taiwan

    Dec 1, 2025, 00:00

  • HTA241 Navigating Clinical Trial Design Under the EU Health Technology Assessment Regulation

    Dec 1, 2025, 00:00

  • HSD81 Overcoming Patient Access Barriers in Complex Conditions: Lessons From Schizophrenia for Broader Healthcare Applications

    Dec 1, 2025, 00:00

  • RWD147 Real-World Assessment Process to Identify Fit-for-Purpose Data Sources to Meet Milestones for Post-Marketing Requirements (PMR), Post Authorization Safety Studies (PASS), and Health Technology Assessment (HTA) Submissions Utilizing S ...

    Dec 1, 2025, 00:00

  • EE173 Cost-Effectiveness of WIC Eligibility Extension in Preventing Maternal Postpartum Depression: US Payers’ Perspective

    Dec 1, 2025, 00:00

  • EE692 The Cost-Effectiveness of an Artificial Intelligence Software for Stroke Imaging and Treatment Decisions in NHS Hospitals

    Dec 1, 2025, 00:00

  • SA21 Comparative Safety of B/F/TAF vs. Other Antiretroviral Therapy Regimens for Treatment-Experienced People With HIV-1: A Systematic Literature Review and Indirect Comparisons Using Multilevel Network Meta-Regression

    Dec 1, 2025, 00:00

  • PCR2 A Collection Of Essays on Patient Centricity in Intervention Development

    Dec 1, 2025, 00:00

  • HTA109 Development of a Unique Tool for Assessing the Feasibility of an External Control Arm Study

    Dec 1, 2025, 00:00

  • PCR169 Patient and Caregiver Recommendations for Person-Centered Oncology Clinical Trial Design: A Qualitative Study

    Dec 1, 2025, 00:00

  • HTA108 Development of a Multidimensional HTA Evaluation for the Introduction of Clesrovimab in Pediatric RSV Prevention: An Integrated Methodological Approach

    Dec 1, 2025, 00:00

  • CO119 Exploring the Association Between Treatment Effects on Cure Rates and Overall Survival (OS) in Resected Stage II/III Melanoma: A Correlation Meta-Analysis (CMA) of Randomized Controlled Trials (RCTs)

    Dec 1, 2025, 00:00

  • P35 Incorporating Environmental Impacts Into Budget Impact Models: A Case Study of CAR-T Therapies in France

    Dec 1, 2025, 00:00

  • EE706 The Economic Value of Diagnostic Strategies in Hepatitis D: A Methodological Review of Cost-Effectiveness Models

    Dec 1, 2025, 00:00

  • EPH277 Validation Between Antidepressant Treatment Failure Proxy and PHQ-9 Score in Major Depressive Disorder Using a Linked Insurance Claims and Electronic Health Record Dataset

    Dec 1, 2025, 00:00

  • CO202 Real-World Effectiveness of Oral Semaglutide in Thai Patients With Type 2 Diabetes: An Observational Single-Arm Multicenter Retrospective Cohort Study (REALISED)

    Dec 1, 2025, 00:00

  • EE367 Economic Burden of the Adverse Events During Treatment of Metastatic Breast Cancer (mBC) HR(+) HER2(-) Patients in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • EE97 Budget Impact Analysis of Subcutaneous Ocrelizumab for Relapsing Multiple Sclerosis in Italy: A Hospital Perspective

    Dec 1, 2025, 00:00

  • EPH135 Impact of Resmetirom on Liver Transplant Demand and Outcomes in US Patients With MASH

    Dec 1, 2025, 00:00

  • RWD139 Quality and Impact of Real-World Data in Chronic Disease Research: Insights From Retrospective Studies Using the Hospital Episode Statistics (HES) Database

    Dec 1, 2025, 00:00

  • HTA26 Advancing Patient Involvement in Health Technology Assessment

    Dec 1, 2025, 00:00

  • MSR188 Single-Agent vs. Multi-Agent RAG for Health Economic Model Replication: A Comparative Evaluation

    Dec 1, 2025, 00:00

  • MSR25 An Integrated Web-Based Approach to Survival Analysis and Extrapolation for Economic Modeling

    Dec 1, 2025, 00:00

  • HPR197 The Disease Burden of Respiratory Syncytial Virus Among the Adult Population in Greece

    Dec 1, 2025, 00:00

  • EE65 Assessing Time Tradeoff Utilities in Health States of Organic Hypogonadotropic Hypogonadism: A Pilot Study in Brazil

    Dec 1, 2025, 00:00

  • CO197 Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nirogacestat in Patients With Desmoid Tumors

    Dec 1, 2025, 00:00

  • EE234 Cost-Effectiveness of an AI-Based Smartphone App for the Early Detection of Skin Cancer: A Decision Tree Analysis

    Dec 1, 2025, 00:00

  • MT21 Generative A-Powered Extraction of Immune-Related Adverse Events From Oncology Case Reports

    Dec 1, 2025, 00:00

  • HTA14 A Review of NICE Technology Appraisals in Oncology Including Economic Evaluations With Time-Varying Network Meta-Analysis

    Dec 1, 2025, 00:00

  • HTA296 Scoping the Future: Using NICE Scopes to Inform PICO Prediction for EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • HTA224 Limited Duration vs. Treat-to-Progression Approaches for New Therapies in Hemato-oncology: Impact at HTA

    Dec 1, 2025, 00:00

  • HTA110 Differences in the Reimbursement Pathway for Ultraorphan Therapies in England and Ireland

    Dec 1, 2025, 00:00

  • HPR212 Extent and Causes of the Collapse in the Registration of Innovative Medications in Lebanon: A Mixed-Methods Analysis

    Dec 1, 2025, 00:00

  • RWD116 Leveraging a Multicountry Real-World Data Observatory to Monitor Respiratory Tract Infections and Evaluate Public Health Interventions in Europe

    Dec 1, 2025, 00:00

  • HSD8 Assessing the Environmental Value of Semaglutide: Reduction in GHG Emissions Resulting From the Treatment of Obese Individuals With Type 2 Diabetes

    Dec 1, 2025, 00:00

  • SA88 Systematic Literature Review on the Burden and Economic Impact of Invasive Meningococcal Disease in Adolescents and Young Adults in France, Italy, Spain, and Germany

    Dec 1, 2025, 00:00

  • CO152 Inefficiencies of Off-Label Therapy in the Prevention of Generalized Pustular Psoriasis (GPP) Flares: Real-World Evidence From Europe

    Dec 1, 2025, 00:00

  • EE162 Cost-Effectiveness Analysis of Pembrolizumab in Combination With Enfortumab Vendotin for First-Line Treatment of Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

    Dec 1, 2025, 00:00

  • PCR109 Health Utility and Indirect Costs of Neuromuscular Disease Through a Patient-Centered Lens: A National Patient and Caregiver Survey

    Dec 1, 2025, 00:00

  • CO238 The Clinical Impact of Screening Blood Donations for Hepatitis E Virus in Catalonia

    Dec 1, 2025, 00:00

  • EE610 Population Impact of Performing BRCA1/2 Testing to Guide Metastatic Castration-Resistant Prostate Cancer Treatment in Spain

    Dec 1, 2025, 00:00

  • HTA242 Navigating Evidence Requirements for Joint Clinical Assessment (JCA): Practical Considerations for Systematic Literature Review (SLR) and Indirect Treatment Comparisons (ITCs)

    Dec 1, 2025, 00:00

  • SA99 Understanding Heterogeneity in the Classification of Locally Advanced Cancer: Analysis of Clinical Trial Records From the Past 2 Years (2023-2025)

    Dec 1, 2025, 00:00

  • EE554 Informing Value-Based Pricing: Cost-Effectiveness Analysis of a Hypothetical First-Line Therapy for Metastatic Pancreatic Cancer

    Dec 1, 2025, 00:00

  • HTA373 Worth Their Weight? Cost-Effectiveness and Access Decisions for GLP-1 and GIP/GLP-1 Therapies

    Dec 1, 2025, 00:00

  • PT9 Mind the Gap: Understanding the Global Imbalances in Spending for Innovative Medicines

    Dec 1, 2025, 00:00

  • RWD177 Switching Within vs. Outside the TNFi Class Following TNFi Failure in Patients With Crohn’s Disease (CD) in Europe: A Meta-Analysis of Real-World Outcomes

    Dec 1, 2025, 00:00

  • CO171 NMAs of Systemic Therapies for Advanced Biliary Tract Cancer: A Systematic Review and Critical Appraisal Using RoB NMA

    Dec 1, 2025, 00:00

  • EE219 Cost-Effectiveness Analysis of Secukinumab for Moderate to Severe Hidradenitis Suppurativa in Portugal

    Dec 1, 2025, 00:00

  • SA10 Alternative Evidence Generation Approaches for Rare Diseases: Addressing HEOR and Healthcare Decision-Making Challenges

    Dec 1, 2025, 00:00

  • HTA56 Beyond the Surfa Health Technology Assessment and Reimbursement for Inflammatory or Autoimmune Disorders With Cosmetic and Dermatological Manifestations

    Dec 1, 2025, 00:00

  • CO49 Clinical Outcomes In HTA Appraisal Reports Of Oncology Medicines In Portugal: A Cross-Sectional Analysis

    Dec 1, 2025, 00:00

  • MSR174 Psychometric Evaluation of the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire Item-10 (Physical Fatigue) and Idiopathic Thrombocytopenic Purpura Bleeding Scale Using LUNA 3 Phase 3 Trial Data

    Dec 1, 2025, 00:00

  • HTA93 Cost-Effectiveness Analysis of Gemcitabine Nabpaclitaxel Combination, Modified FOLFIRINOX, and SIROX As First-Line Therapy for Pancreatic Cancer

    Dec 1, 2025, 00:00

  • HTA18 Acceptance of Artificial Intelligence in Evidence and Dossier Development by Global HTA Agencies

    Dec 1, 2025, 00:00

  • HTA352 Using External Clinical Evidence to Inform Local Health Policy: The Tradeoff Between Early Access and Uncertainty

    Dec 1, 2025, 00:00

  • HPR229 Unintended Consequences of MFN Pricing: Global Access Risks and Revenue Impact

    Dec 1, 2025, 00:00

  • EE551 Indirect Costs Associated With Pneumococcal Disease: A Global Targeted Literature Review

    Dec 1, 2025, 00:00

  • HTA320 The Impact of Using England Real-World Evidence to Establish the NICE Severity Modifier in Metastatic Urothelial Carcinoma (MUC)

    Dec 1, 2025, 00:00

  • CO34 Budget Impact of a PreTRM-Guided Preventive Bundle for Preterm Birth in Low-Risk Pregnancies: A Microsimulation Study Using PRIME Trial Data

    Dec 1, 2025, 00:00

  • HPR142 Mind the Gap: Exploring Variation in Guidelines for Indirect Treatment Comparison (ITC) Across Europe

    Dec 1, 2025, 00:00

  • PCR93 Exploring Quality of Life in Duchenne Muscular Dystrophy: Insights From Qualitative Patient and Caregiver Interviews

    Dec 1, 2025, 00:00

  • MT48 What Is the HTA Process for Medical Technologies in Scotland?

    Dec 1, 2025, 00:00

  • MSR227 Zoom Out: Simplifying Complex Health Economic Model Structure Through Artificial Intelligence

    Dec 1, 2025, 00:00

  • HTA71 Challenges in PICO Definition for HTDs: Lessons From Durvalumab Exercise

    Dec 1, 2025, 00:00

  • EE242 Cost-Effectiveness of Connected Injection Device for Pediatric Growth Hormone Deficiency in Spain: A Scenario-Based Microsimulation Analysis Using Real-World Data

    Dec 1, 2025, 00:00

  • EE61 Assessing the Economic Impact of Biosimilars in Europe: A Cost Analysis of Infliximab, Trastuzumab, and Rituximab

    Dec 1, 2025, 00:00

  • EE473 First-Line Immunotherapies for Advanced Biliary Tract Cancer: A Systematic Review of Economic Studies

    Dec 1, 2025, 00:00

  • RWD22 Assessment of Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland

    Dec 1, 2025, 00:00

  • MSR195 The AI-in-RWE Transparency (AIRT) Checklist: Essential and Desirable Standards for AI-Enhanced Real-World Evidence

    Dec 1, 2025, 00:00

  • EE364 Economic Burden of Progressive Pulmonary Fibrosis (PPF) in the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • EE253 Cost-Effectiveness of High-Dose Trivalent Influenza Vaccine in the Elderly: A Cohort-Based Economic Model From the Italian NHS Perspective

    Dec 1, 2025, 00:00

  • EPH220 Studying Paternal Drug Exposures and Offspring Outcomes: A Feasibility Assessment of 11 Large European Databases

    Dec 1, 2025, 00:00

  • EE527 Impact of CFTR Modulator Initiation on Direct Medical Costs for People With Cystic Fibrosis

    Dec 1, 2025, 00:00

  • RWD184 Treatment Patterns and Healthcare Costs of Newly Diagnosed Type 1 Diabetes Patients: A Retrospective Real-World Study of Hospital Care in Tianjin, China

    Dec 1, 2025, 00:00

  • EE480 Genomic Testing for Early Breast Cancer: Assessing the Value of Next-Generation Sequencing

    Dec 1, 2025, 00:00

  • HSD52 From Agricultural Waste to Clinical Value: An Economic and Operational Analysis of Paddy Straw-Based Utensils in Malaysian Hospital

    Dec 1, 2025, 00:00

  • EE28 A Real-World Retrospective Cohort Study Characterizing Healthcare Resource Utilization and Costs Among Patients With MMN in the United States

    Dec 1, 2025, 00:00

  • EE210 Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole for the Treatment of Invasive Aspergillosis in Morocco

    Dec 1, 2025, 00:00

  • MSR211 Understanding Public Values in Digital Mental Health Using the Principles, Policies, and Patients’ Framework

    Dec 1, 2025, 00:00

  • HTA52 Barriers to Reimbursement: Characteristics of Unfunded Medicines in Ireland (2006-2021)

    Dec 1, 2025, 00:00

  • HTA195 Impact of the Societal Perspective on HTA Decision Making in Rare Diseases

    Dec 1, 2025, 00:00

  • PCR5 A Data-Driven Framework for Rare Disease Protocol Design: Integrating Real-World Evidence, Patient Perspectives, and Regulatory Guidance

    Dec 1, 2025, 00:00

  • HPR74 European and US Drug Shortages: A Critical Analysis of Key Trends and Causes

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • MT13 Defining Decision-Making Criteria for Glaucoma Surgery in Non-Refractory, Moderate to Severe Open-Angle Glaucoma: A Stakeholder Analysis Across Multiple Countries with Distinct Payer Archetypes to Support a Multi-Criteria Decision Anal ...

    Dec 1, 2025, 00:00

  • OP14 Linking Data to Care: Mining the Pathways of Oncology

    Dec 1, 2025, 00:00

  • PCR32 Bimekizumab Improves Work Productivity in Patients With Hidradenitis Suppurativa: 2-Year Results From BE HEARD EXT

    Dec 1, 2025, 00:00

  • HTA49 Associations of Product-Specific and Clinical Evidence Quality Characteristics With Health Technology Assessment Outcomes: A Quantitative Assessment of Appraisals for Drugs for Rare Diseases in England and Germany

    Dec 1, 2025, 00:00

  • CO71 Development of a New, Adaptable Patient-Reported Outcome Measure of Treatment Satisfaction

    Dec 1, 2025, 00:00

  • HSD85 Persistence of Anticholinergic Agents in Patients With Overactive Bladder: A Cohort Study From the French National Health Insurance Claim Database (SNDS)

    Dec 1, 2025, 00:00

  • HTA275 Provisional Listing of Digital Healthcare Applications Digas Improves Patients' Access to Healthcare in Germany

    Dec 1, 2025, 00:00

  • EE520 How Can Intravitreal Aflibercept 8 mg Impact Treatment Burden and Costs in European Patients With Diabetic Macular Edema? From Clinical Trials to Clinical Practice

    Dec 1, 2025, 00:00

  • MSR128 Implementing SISAQOL Recommendations: Insights From Cancer Clinical Trials

    Dec 1, 2025, 00:00

  • RWD187 Understanding Treatment Preferences in Highly Sensitized ESKD Patients: A Latent Profile Analysis of Discrete Choice Data

    Dec 1, 2025, 00:00

  • RWD141 Real-World Evidence Study on the Resource Impact of Subcutaneous vs. Intravenous Atezolizumab in an NHS Cancer Center

    Dec 1, 2025, 00:00

  • EE503 Healthcare Resource Use Among Patients With Chronic Rhinosinusitis With Nasal Polyps in the United Kingdom: Results of an Expert Elicitation Survey

    Dec 1, 2025, 00:00

  • EE316 Danicopan: A Dominant Option for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Residual Hemolytic Anemia in Spain

    Dec 1, 2025, 00:00

  • MSR138 Linking Specialty Pharmacy Data With Healthcare Claims Data in a Rare Disease: Comprehensively Characterizing Patients With Hereditary Angioedema Treated With Berotralstat

    Dec 1, 2025, 00:00

  • HPR201 The French Transitional Coverage Pathway (PECT) for Innovative Therapeutic Medical Devices: A Four-Year Retrospective Analysis

    Dec 1, 2025, 00:00

  • Methodological Challenges With Conducting Health Economic Evaluations in the Critical-Care Context

    Dec 1, 2025, 00:00

  • EPH153 Knowledge and Attitudes Regarding the HPV Vaccine Among Secondary School Students

    Dec 1, 2025, 00:00

  • HPR108 Global Payer Policies Potentially Impacting Pharma Pricing and Market Access Strategies: A Review of Five Key Trends Shaping Pharma Future

    Dec 1, 2025, 00:00

  • HTA233 Middle East NICE Move Towards Standardized Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE146 Comparative Analysis of Different Crown Materials for Dental Prosthesis From Budget in Wartime in Ukraine

    Dec 1, 2025, 00:00

  • PCR92 Exploring Knowledge Attitudes and Perspectives on Respiratory Viruses Vaccination Among Older Adults in the US

    Dec 1, 2025, 00:00

  • SA1 A Comprehensive Assessment of Clinical Studies on Artificial Intelligence-Enabled Interventions: Uncovering Trends and Potential Implications

    Dec 1, 2025, 00:00

  • MSR10 A Two-Stage Bayesian Approach for Real-World Cost-Effectiveness Analysis: Combining Inverse Probability Weighting With Gamma-Beta Regression Model

    Dec 1, 2025, 00:00

  • EPH19 Artificial Intelligence in Evidence Synthesis: A Systematic Review and Meta-Analysis of Emerging Biologics for Improving Skeletal Health in Osteogenesis Imperfecta

    Dec 1, 2025, 00:00

  • RWD180 The Impact of Socioeconomic and Clinical Factors on Mental Healthcare Expenditure: Enabling Quality Managed Care Decisions

    Dec 1, 2025, 00:00

  • EE645 Reforming the Delivery of Smoking Cessation: A Distributional Cost-Effectiveness Analysis of Providing Smoking Cessation as Part of Targeted Lung Cancer Screening in England

    Dec 1, 2025, 00:00

  • HPR76 Evaluating the Effectiveness of Interventions to Reduce Gender Disparities in Healthcare: An Overview of Literature Reviews

    Dec 1, 2025, 00:00

  • EE585 Modeling the Clinical and Economic Impact of DPP-4 Inhibitors in Uncontrolled T2D

    Dec 1, 2025, 00:00

  • EE48 An Evaluation of the Cost of Treatment for Low-Back Pain Among Patients Attending Public Healthcare Facilities in Nigeria

    Dec 1, 2025, 00:00

  • RWD50 Data Linkage to Support Real-World Evdence in Rare Disease

    Dec 1, 2025, 00:00

  • HPR107 Global Access to Innovative Medicines in 2025: Europe’s Gaps and the UK’s Continued Decline

    Dec 1, 2025, 00:00

  • EE46 An Economic Evaluation of Risankizumab vs. Adalimumab in Moderate to Severe Plaque Psoriasis Adult Patients in Egypt

    Dec 1, 2025, 00:00

  • EE12 A Cost-Effectiveness Evaluation of Blinatumomab Use in the Measurable Residual Disease-Negative Remission State to Treat Adults With Philadelphia-Chromosome–Negative B-cell Acute Lymphoblastic Leukemia in France

    Dec 1, 2025, 00:00

  • CO88 Effectiveness of Subcutaneous Natalizumab in Multiple Sclerosis: Real-World Evidence From a Finnish Registry Study

    Dec 1, 2025, 00:00

  • EE659 Societal and Economic Impact of Long-Acting Injectable Buprenorphine (LAIB) Compared With Standard Opioid Substitution Therapy (OST) in France

    Dec 1, 2025, 00:00

  • EE317 Danicopan in Addition to the Component 5 Inhibitor C5i Ravulizumab for the Treatment of Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Residual Hemolytic Anemia in Gree A Cost Utility Analysis

    Dec 1, 2025, 00:00

  • PCR137 Improving Time to Patient: Insights From the Canadian Cancer Treatment Hackathons

    Dec 1, 2025, 00:00

  • SA66 Measurement Properties of the EQ-5D in Hematological Cancers: A Systematic Review

    Dec 1, 2025, 00:00

  • EE339 Do The Guardrails Have Any Effect at All? An Analysis of the Impact of the 2022 FINSTG Guardrails on the German AMNOG Process

    Dec 1, 2025, 00:00

  • MSR52 Can Generative AI Automate Health Economic Model Verification?

    Dec 1, 2025, 00:00

  • HTA95 Cost-Effectiveness Analysis of RSVpreF Vaccine for RSV Prevention in Older Adults Under Situation of the National Vaccination Program in Taiwan: A Study on Economic and Clinical Advantages

    Dec 1, 2025, 00:00

  • PCR123 Hybrid Digital Support for Patients Receiving Adalimumab Therapy for Immune-Mediated Inflammatory Disorders: 12-Month Persistence and Impact on Adherence

    Dec 1, 2025, 00:00

  • EE289 Costs Associated With the Administration, Postinfusion Monitoring, and Management of Adverse Events (AEs) Related to Novel Drugs for Second-Line (2L+) Treatment of Small-Cell Lung Cancer (SCLC)

    Dec 1, 2025, 00:00

  • HPR55 Digital Twins: Hype or Hope for Better Health Outcomes

    Dec 1, 2025, 00:00

  • HPR236 Value of Patient-Reported Outcomes Data in Food and Drug Administration Labeling of Oncology Drugs to Payers in the United States

    Dec 1, 2025, 00:00

  • CO261 Using Structured Expert Elicitation to Estimate Long-Term Organ Damage Risk in an Ultrarare Condition: A STEER Case Study

    Dec 1, 2025, 00:00

  • EE664 Societal Value of Intravitreal Injections for Retinal Vascular Diseases in the National Reimbursement Drug List in China

    Dec 1, 2025, 00:00

  • HTA362 What Drives European Union (EU) Health Technology Assessment (HTA) Decisions in Melanoma? A Targeted Review on Clinical Evidence Critiques

    Dec 1, 2025, 00:00

  • EE314 Cost-Utility of Protocoled Practice Nurse-Led Care for Children With Asthma in Primary Care

    Dec 1, 2025, 00:00

  • EE479 Gender Differences in the Economic Burden of Alcohol Use in Belgium

    Dec 1, 2025, 00:00

  • CO132 Herpes Zoster Hospitalization Rates in Germany: A Retrospective Database Analysis

    Dec 1, 2025, 00:00

  • HSD67 Knowledge and Practices Regarding Expired Medications Among Saudi Citizens

    Dec 1, 2025, 00:00

  • MSR85 Empirical Evidence on Impact by Accounting for Cluster Effect Within Patients in Cohort Studies Evaluating Comparative Effectiveness of Dental Treatments: A Meta-Epidemiological Study

    Dec 1, 2025, 00:00

  • HSD94 Real-World Evidence on Treatment Patterns and Guidelines in Patients With Advanced Merkel Cell Carcinoma Across the US and Europe

    Dec 1, 2025, 00:00

  • EE504 Healthcare Resource Use and Costs Associated With Herpes Zoster Among Adults Aged 18 Years or Older in England: A Large Retrospective Cohort Study Clinical Practice Research Datalink 2012-2019

    Dec 1, 2025, 00:00

  • HTA24 Adoption and Evidence Generation in NICE Early Value Assessments (EVA) for Medtech: Trends Across 2023-2025

    Dec 1, 2025, 00:00

  • RWD81 Evolving Trends in Patient Demographics and Diagnosis in Gastric Cancer: A Real-World Analysis From US Community Oncology Practices From 2014 to 2024

    Dec 1, 2025, 00:00

  • PCR48 Common Criticism of Patient-Reported Outcomes (PRO) in Health Technology Assessments (HTA) by the Institute for Quality and Efficiency in Healthcare (IQWiG) in Breast Cancer and Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • SA97 Therapeutic Potential of Bispecific Antibodies in Adenocarcinoma: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EPH130 Hospitalizations for Myasthenia Gravis: Pre- and Post-COVID Trends

    Dec 1, 2025, 00:00

  • PCR58 Development of a Content-Valid Patient-Reported Outcome (PRO) Measure for Adults With Glycogen Storage Disease Type 1a (GSD1a): The GSD1a Symptom Diary-Adult Version

    Dec 1, 2025, 00:00

  • HTA252 NICE Decisions in the Southwest Quadrant

    Dec 1, 2025, 00:00

  • HTA123 Efficient and High-Quality Decision Making: An Exploration of Disease-Specific Reference Models at NICE

    Dec 1, 2025, 00:00

  • HTA361 What Did Time Reveal Evaluating the Accuracy of Parametric Model Predictions Against Long-Term Observed Data for Larotrectinib?

    Dec 1, 2025, 00:00

  • HTA292 Role of PROs in HTA and Reimbursement Decisions Across UK, Germany, France, Italy, and Spain

    Dec 1, 2025, 00:00

  • HPR137 Mapping PBS Drug Pathways in Australia: A Framework and Interactive Tool for Category-Specific Pricing Calculations

    Dec 1, 2025, 00:00

  • MSR104 Exploring Nonproportional Hazards Multi-Level Network Meta-Regression (ML-NMR) for Survival Extrapolations in Oncology

    Dec 1, 2025, 00:00

  • CO18 Assessment of Oncology Analog HTA Outcomes and Evidence Needs in France and Germany

    Dec 1, 2025, 00:00

  • EE390 Economic Evaluation of the RESET Study Weight Loss Phase: Impact on Event Risk Reduction and Cost-Effectiveness in Type 2 Diabetes Management

    Dec 1, 2025, 00:00

  • MT20 Gender Inequalities in Aortic and Mitral Valve Replacement and Repair Procedures in Germany

    Dec 1, 2025, 00:00

  • EE549 Incorporating Equity-of-Access Into Health Economic Evaluations: Surgical Task-Shifting for C-Sections in Sierra Leone

    Dec 1, 2025, 00:00

  • RWD178 Systematic Review of Effectiveness of SGLT2 Inhibitors in Patients With Type 2 Diabetes With Focus on Glucose Levels, Cardiovascular Events, and Renal Function

    Dec 1, 2025, 00:00

  • CO232 Systematic Review of Real-World Data on the Effectiveness and Safety Profiles of First-Line Therapies in Chronic Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • EE611 Population Reference Costs for Average Total Annual Care in the UK National Health Service for 11 Common Diseases or Conditions vs. Matched Controls

    Dec 1, 2025, 00:00

  • HTA353 Utilization of Real-World Evidence (RWE) in AMNOG Dossiers Following the 2024 GBA Revision of Module 3 Requirements

    Dec 1, 2025, 00:00

  • EPH193 Prevalence of Post-Traumatic Stress Disorder Among Ambulance Officers During the COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • HTA103 Defining Unavoidable Uncertainty in HTA: Towards More Flexible and Adapted Approaches for Promising Treatments

    Dec 1, 2025, 00:00

  • CO125 Garbage In, Garbage Out: Can AI Reduce the Impact of Human Error in eCOA Localized Text Migration?

    Dec 1, 2025, 00:00

  • RWD44 COPD-Asthma Overlap in Brazilian Private Healthcare: Clinical Profiles and Outcomes from a Real-World Analysis

    Dec 1, 2025, 00:00

  • HTA164 Get JCA-Ready: Mastering PROs for Market Access Success

    Dec 1, 2025, 00:00

  • EE74 Bimekizumab Cost per Responder Analysis Compared to Other Licensed Interleukin Inhibitors at Week 52 for the Treatment of Psoriatic Arthritis: A United Kingdom Perspective

    Dec 1, 2025, 00:00

  • EE691 The Cost-Effectiveness of a Novel Scalp Cooling Device to Alleviate Chemotherapy-Induced Alopecia in Patients With Early Breast Cancer

    Dec 1, 2025, 00:00

  • CO31 Breast Cancer Overall Survival in France

    Dec 1, 2025, 00:00

  • PCR133 Impact of Transfusion-Dependent Thalassemia on Adult Patients’ Health-Related Quality of Life and Work Productivity in the Kingdom of Saudi Arabia and United Arab Emirates

    Dec 1, 2025, 00:00

  • HTA230 Methodological Acceptability of the Economic Analyses Assessed by the HAS in 2024

    Dec 1, 2025, 00:00

  • CO204 Real-World Efficacy Outcomes for Patients With Relapsed/Refractory Multiple Myeloma (RRMM) From the Flatiron Health Database

    Dec 1, 2025, 00:00

  • EE735 Treatment Patterns and Economic Outcomes in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US: A Real-World Claims Database Analysis

    Dec 1, 2025, 00:00

  • CO41 Children With Asthma Receiving Dupilumab Plus Medium-Dose Inhaled Corticosteroids Had Improved Exacerbations, Lung Function, and Airway Inflammation Compared To Those Receiving Placebo Plus High-Dose Inhaled Corticosteroids

    Dec 1, 2025, 00:00

  • HSD74 Missed Opportunities in the Diagnosis and Management of Stage 3 Chronic Kidney Disease in General Practi Insights From the Italian THIN Database

    Dec 1, 2025, 00:00

  • EE603 Organizational and Environmental Impact of Switching From Intravenous to Subcutaneous Immune Checkpoint Inhibitors (ICIs) in Fran A Real-World Analysis Using PMSI Data

    Dec 1, 2025, 00:00

  • P25 Optimizing the Use of Excess Hazard Models in Survival Analysis: Considering Disease Severity and Follow-up Maturity

    Dec 1, 2025, 00:00

  • EE164 Cost-Effectiveness Analysis of Tenecteplase vs. Alteplase for Adults With Acute Ischemic Stroke (AIS) in Greece

    Dec 1, 2025, 00:00

  • PCR247 Treatment Discontinuation in Idiopathic Pulmonary Fibrosis: A Systematic Review of Antifibrotic Drug Use and Tolerability

    Dec 1, 2025, 00:00

  • CO65 Costs and Consequences of Cardiovascular Toxicity Due to Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • PT30 An Exploration of Implementing Herd Immunity Into Static Models for Economic Evaluation of Vaccines

    Dec 1, 2025, 00:00

  • EE163 Cost-Effectiveness Analysis of Ribociclib With Endocrine Therapy for Treatment With Premenopausal Women With HR Positive HER2 Negative Early Breast Cancer in the UK

    Dec 1, 2025, 00:00

  • MT42 The Unique Value of Detecting Preeclampsia: Comparing Health Economic Analyses of Novel Diagnostics With the ISPOR Value Flower

    Dec 1, 2025, 00:00

  • PCR40 Caregiver QALYs Deserve Better: Why It's Time for a Methodological Rethink

    Dec 1, 2025, 00:00

  • RWD136 Potential Nephrocalcinosis Risk Linked to Nusinersin: Insights from FAERS-Based Signal Detection and Molecular Docking

    Dec 1, 2025, 00:00

  • HTA170 Have Delays in Vaccine Market Access Improved in Europe and the US Over the Last Decade?

    Dec 1, 2025, 00:00

  • HTA247 Navigating Parallel Joint Scientific Consultations Under EU HTA Regulation: Key Internal Considerations for Health Technology Developers

    Dec 1, 2025, 00:00

  • EE136 Comparative Assessment of Health-Related Quality of Life Among the Lebanese Population Pre- and Post-COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • Health-Economic Evaluation of COVID-19 Updated Booster Vaccination and Age-Related Cost Outcomes

    Dec 1, 2025, 00:00

  • EE54 Application and Future Potential of Generative Artificial Intelligence (Gen AI) And Large Language Model (LLM) In Health Economics and Outcomes Research (HEOR)

    Dec 1, 2025, 00:00

  • EE306 Cost-Utility Analysis of Ocrelizumab for Treating Relapsing Multiple Sclerosis in Austria

    Dec 1, 2025, 00:00

  • CO113 Evolution of MRD in Hemato-Oncology Clinical Development

    Dec 1, 2025, 00:00

  • EE357 Economic Burden of Chronic Obstructive Pulmonary Disease (COPD) in India: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • CO96 Efficacy of Pregabalin and High-Concentration (179 mg) Capsaicin Patch in Peripheral Neuropathic Pain: A Review of Studies ≥ 26 Weeks' Duration

    Dec 1, 2025, 00:00

  • MSR131 Improving Kidney Exchange Program Effectiveness and Equity by Using Allele and Eplet HLA Compatibility Technologies

    Dec 1, 2025, 00:00

  • EE223 Cost-Effectiveness and Budget Impact of High-Dose Trivalent Influenza Vaccine Efluelda® in Older Adults: A Greek Healthcare System Perspective

    Dec 1, 2025, 00:00

  • RWD191 Validating a Medication Adherence Index in Large Urban Population

    Dec 1, 2025, 00:00

  • EPH39 Changes in the Epidemiological Indicators of Female Infertility in Europe 1991-2021

    Dec 1, 2025, 00:00

  • EE262 Cost-Effectiveness of Modifying Cardiovascular Disease Risk Factors in Qatar Using the Productivity-Adjusted Life Years (PALY) Metric

    Dec 1, 2025, 00:00

  • EE529 Impact of Dupilumab on Mental Health Service Utilization in Patients With Atopic Dermatitis in a Colombian Health Insurance Provider: An Observational Real-World Practice Study

    Dec 1, 2025, 00:00

  • EE245 Cost-Effectiveness of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective

    Dec 1, 2025, 00:00

  • PCR111 Healthcare Professionals-Perceived Benefits and Opportunities to Improve an Electronic Patient-Reported Outcomes (ePRO)-Based Remote Symptom Monitoring (RSM) Program During Cancer Treatment

    Dec 1, 2025, 00:00

  • CO23 Association Between Objective Response and Overall Survival in BRAF V600e-Mutant Metastatic Colorectal Cancer: An Analysis of the BEACON CRC Trial

    Dec 1, 2025, 00:00

  • EE703 The Economic Burden of Parkinson's Disease in the Netherlands: From Societal Impact to Investments in Health Solutions

    Dec 1, 2025, 00:00

  • HTA268 Patient-Centered PICO Scoping in EU HTA: A Pilot Study for Structured Consensus Building Using a Delphi Panel

    Dec 1, 2025, 00:00

  • HTA355 Value Framework to Support Payer Decisions in Hemophilia in Türkiye

    Dec 1, 2025, 00:00

  • HSD49 Evaluation of the Effectiveness of Targeted Radiofrequency Therapy in Impingement Syndrome

    Dec 1, 2025, 00:00

  • MSR22 AI-Assisted Time-to-Event Projection: A Case Study and Broader Potential

    Dec 1, 2025, 00:00

  • P62 EQ-5D Analysis in a Rare Disease: Utilities Across Disease Stages in Multiple-System Atrophy

    Dec 1, 2025, 00:00

  • CO212 Resistance-Driven Treatment Failure: A Challenge to HCV Elimination in Pakistan

    Dec 1, 2025, 00:00

  • EE227 Cost-Effectiveness as Part of the German AMNOG Process Analyzing the 2025 SVR Proposal and Its Implementation Challenges

    Dec 1, 2025, 00:00

  • EE521 How Cost-Effectiveness and Budget Impact Drive Pricing and Reimbursement: Insights From an International Comparative Study

    Dec 1, 2025, 00:00

  • SA93 The Health Economic Case for AI in Radiology: A Systematic Review and Appraisal of Evaluation Quality and Methods

    Dec 1, 2025, 00:00

  • CO103 Evaluating EU-HTA PICO Exercise Outcomes: Duration of Response and Time to Response in Hepatocellular Carcinoma Using Randomization-Preserving Methods with IMbrave150 Data

    Dec 1, 2025, 00:00

  • PCR166 Optimizing a New Patient-Reported Outcome Instrument for Proliferative Diabetic Retinopathy: A Psychometric Study

    Dec 1, 2025, 00:00

  • HPR36 Bridging the Access Gap: The Role of Non-Public Access Partnerships for Oncology Treatments in China

    Dec 1, 2025, 00:00

  • EPH20 Assessing Pharmaceutical Innovation in Europe: Therapeutic Advances vs. Unmet Public Health Need

    Dec 1, 2025, 00:00

  • P21 Real-World Evidence of Healthcare Resource Utilization in Cystic Fibrosis (CF) Patients Treated With Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in France Using Long-term Data From the SNDS Database Linked to the French CF Registry: ...

    Dec 1, 2025, 00:00

  • HSD15 Bridging Systemic Access Gaps for Cancer Medicines: A Policy Perspective From the Republic of Moldova

    Dec 1, 2025, 00:00

  • EE26 A Nutrient-Dense Formula in Undernourished Children in Indonesia: An Effective Cost-Saving Strategy

    Dec 1, 2025, 00:00

  • MT29 Mortality and Economic Burden of Revisions After Proximal Femoral Fracture Fixation

    Dec 1, 2025, 00:00

  • HSD69 Localizing a Sequencing Model Using Patient-Level Data to Optimize Outcomes in the First Line of Treatment for Multiple Myeloma in Greece

    Dec 1, 2025, 00:00

  • HTA297 Shifts in the French HTA Transparency Committee’s Use of Indirect Comparisons: Insights From a Systematic Review of the French Transparency Committee (TC) Opinions

    Dec 1, 2025, 00:00

  • MT4 AI-Enabled Wearables for Fitness and Preventive Health

    Dec 1, 2025, 00:00

  • PCR9 A Review of Approaches to Select Instruments and Items to Measure Patient Reported Tolerability in Clinical Trials in Oncology

    Dec 1, 2025, 00:00

  • HTA249 Navigating the Transition: What EU JCA Means for AMNOG Submissions in 2025 and Beyond

    Dec 1, 2025, 00:00

  • CO168 Nephrotoxicity of Antisense Oligonucleotide Therapies in Duchenne Muscular Dystrophy: A Warning or a Challenge?

    Dec 1, 2025, 00:00

  • OP10 Global Access Licensing: An Expert Interview Study with Scientists-Inventors and Directors of Technology Transfer Offices Involved in the Development and Commercialization of COVID-19 Vaccines

    Dec 1, 2025, 00:00

  • EE240 Cost-Effectiveness of Coblation Intracapsular Tonsillectomy in the Management of Sleep-Disordered Breathing and Recurrent Tonsillitis: A Brazilian Perspective

    Dec 1, 2025, 00:00

  • EE665 Socioeconomic and Geographic Inequalities in Colorectal Cancer Care Utilization and Expenditures: A Decomposition Analysis

    Dec 1, 2025, 00:00

  • PCR132 Impact of Shared Treatment Decision Making Between Physicians and Patients on Treatment Satisfaction in Hypertension

    Dec 1, 2025, 00:00

  • EPH247 The Incidence, Mortality, and Survival of Malignant Non-Small Cell Lung Cancer (NSCLC) in the United States: A Surveillance Epidemiology and End Results (SEER) 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • EPH35 Cardiovascular Event Rate and Mortality Among Primary-Prevention Hypercholesterolemia Patients in Japan

    Dec 1, 2025, 00:00

  • P61 Utilizing LLMs to Enhance Patient-Reported Outcome Measures: Application to the EQ-5D and Bolt-ons

    Dec 1, 2025, 00:00

  • MSR117 High-Fidelity Synthetic Patient Pathway Generation and Validation for NSCLC Using A Tabular Variational Autoencoder (TVAE)

    Dec 1, 2025, 00:00

  • EE650 Resource Utilization Among Patients With Epidermolysis Bullo Preliminary Findings From Seven European Countries

    Dec 1, 2025, 00:00

  • HPR163 Price Implications of the Most-Favored Nation Policy on US Oncology Drug Prices

    Dec 1, 2025, 00:00

  • SA84 Screening and Diagnosis of Paroxysmal Nocturnal Hemoglobinuria in Gree Consensus Recommendations From a Multispecialty Expert Panel

    Dec 1, 2025, 00:00

  • PCR68 Elevating the Patient Perspective: Quantifying First-Line Preferences in Locally Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC) Using the Threshold Technique

    Dec 1, 2025, 00:00

  • EE222 Cost-Effectiveness and Budget Impact Analysis of Noninvasive Prenatal Testing (NIPT) for the Identification of Fetal Chromosomal Aneuploidies in Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • HTA22 Adapting to Change: Analysis of Trend Estimation in AMNOG Dossiers Under Revised GBA Guidelines

    Dec 1, 2025, 00:00

  • EE434 Evaluating the Budget Impact of Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) in Patients With Moderate to Severe Asthma in the Saudi Healthcare System

    Dec 1, 2025, 00:00

  • HTA371 Why TSD26 Matters: How Accurate Was Clinical Expert Opinion in Estimating Long-Term Outcomes?

    Dec 1, 2025, 00:00

  • CO110 Evaluating the Repurposing Potential of Statins: Association Between Statin Use and Cognitive Decline in Patients With Mild-to-Moderate Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • HTA51 Balancing Fit and Accuracy: Evaluating Survival Model Projections With Immature Data in Health Technology Assessments

    Dec 1, 2025, 00:00

  • EPH89 Estimating the Incidence and Prevalence of Menorrhagia in the UK Using the THIN Database

    Dec 1, 2025, 00:00

  • PCR59 Development of a Discrete Choice Experiment Survey to Assess Patient Preferences for Treatment of Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • EE43 Advancing Cost-Effectiveness Modeling With R: A Flexible Approach for HTA Submissions

    Dec 1, 2025, 00:00

  • HTA189 HTA Readiness for Tumor-Agnostic Therapies: Lessons From Analogues Across Major Markets

    Dec 1, 2025, 00:00

  • MSR78 Drifting in the Network: Catching Baseline Shifts Before They Wreck Your Network Meta-Analysis

    Dec 1, 2025, 00:00

  • CO150 Indirect Treatment Comparison of Biochemical Control Between Pasireotide Long-Acting Release and Pegvisomant as Second-Line Therapies for Acromegaly, Based on Real-World Evidence

    Dec 1, 2025, 00:00

  • EPH169 Negative Symptoms in Schizophrenia: An Observational Study of Patient Characteristics Cost and Healthcare Resource Utilization From a US Healthcare Database

    Dec 1, 2025, 00:00

  • MSR149 Modeling Price Premiums of Oncology Drugs in Germany: A Cross-Validated Analysis Using XGBoost

    Dec 1, 2025, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2025, 00:00

  • EE134 Comparative Analysis of Composite Materials for Hard Dental Tissue Defect Restorations From Budget Financing in Wartime in Ukraine

    Dec 1, 2025, 00:00

  • PCR152 Mapping the Rare Disease Diagnostic Odyssey of Today: An Adapted Targeted Literature Review (ATLR)

    Dec 1, 2025, 00:00

  • EE202 Cost-Effectiveness Analysis of Generalizing the Lp(a) Dosing in Secondary Prevention in a Population of French Patients With Cardiovascular Disease

    Dec 1, 2025, 00:00

  • EE423 Estimating the Broader Societal Impact of Ocrelizumab for Multiple Sclerosis (MS) in Latin America (LATAM) Using a Social Impact Approach

    Dec 1, 2025, 00:00

  • PCR232 The Impact of Intravesical Instillations on Quality of Life in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

    Dec 1, 2025, 00:00

  • PCR13 Adherence to Anti-VEGF Treatment of Patients With Age-Related Macular Degeneration of Exudative Type (nAMD) and Diabetic Macular Edema (DME) in Gree Evidence From an Expert Panel

    Dec 1, 2025, 00:00

  • CO211 Reducing Premature Cancer Mortality Through Early Stage Treatment: A Markov Model Analysis of Pembrolizumab Across Four Tumor Types

    Dec 1, 2025, 00:00

  • RWD16 An AI-Powered Tool to Identify and Assess Fit-for-Use Registries for Drug Development and Evaluation

    Dec 1, 2025, 00:00

  • RWD23 Association of eGFR Decline and Cardiovascular Outcomes in Chronic Kidney Disease Patients: Feasibility of Frequency Matching Replicating Event-Driven Clinical Trials With Real-World Data Long-Term

    Dec 1, 2025, 00:00

  • RWD39 Comparative Cardiovascular Safety of Romosozumab and Denosumab in Osteoporosis Treatment: A Multinational Real-World Cohort Study

    Dec 1, 2025, 00:00

  • EPH123 Healthcare Resource Utilization and Survival of Patients With HR+/HER2-negative Metastatic Breast Cancer After Treatment With CDK4/6-Inhibitors in Finland

    Dec 1, 2025, 00:00

  • HPR100 France and the Challenge of High-Cost Innovative Drug Expenditures in Hospitals

    Dec 1, 2025, 00:00

  • PCR122 How Are Clinical Trials for Breast Cancer Treatments Currently Being Designed? A Clinical Trial Database Analysis

    Dec 1, 2025, 00:00

  • P1 Predicting EQ-5D Index Scores: A Comparison Study of Machine Learning and Statistical Methods on Health Survey for England Data

    Dec 1, 2025, 00:00

  • CO136 Impact of Different CV Risk Estimation Methods on Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • RWD54 Decoding Atorvastatin-Induced Arthritis: A Systems Pharmacology Approach Integrating Pharmacovigilance, Bioinformatics, and Pathway Enrichment

    Dec 1, 2025, 00:00

  • HTA251 NICE National Institute for Health and Care Excellence Highly Specialized Technology Evaluations: Use of Pivotal Clinical Trial Outcomes to Inform Relative Treatment Effect and Utilities

    Dec 1, 2025, 00:00

  • HPR20 An Analysis of Differences in Patient Access to CGRP Migraine Treatments in the Nordic Region

    Dec 1, 2025, 00:00

  • HTA216 Key Challenges Associated With Recent NICE Appraisals for Oncology Targeted Treatments

    Dec 1, 2025, 00:00

  • Validating Loon Lens 1.0 for Autonomous Abstract Screening and Confidence-Guided Human-in-the-Loop Workflows in Systematic Reviews

    Nov 1, 2025, 00:00

  • Health Economics and Outcomes Research in the New Era of Artificial Intelligence: Catch Me If You Can

    Nov 1, 2025, 00:00

  • Author Reply

    Nov 1, 2025, 00:00

  • A Taxonomy of Generative Artificial Intelligence in Health Economics and Outcomes Research: An ISPOR Working Group Report

    Nov 1, 2025, 00:00

  • Roles of Artificial Intelligence--Based Synthetic Data in Health Economics and Outcomes Research

    Nov 1, 2025, 00:00

  • Development and Use of Cognition Bolt-Ons for the EQ-5D-3L and EQ-5D-5L: A Systematic Review

    Nov 1, 2025, 00:00

  • Reevaluating Artificial Intelligence–Enabled Emergency Care in the National Health Service:  Economic Value, Diagnostic Realities, and Ethical Challenges

    Nov 1, 2025, 00:00

  • Generative Artificial Intelligence to Automate the Adaptation of Excel Health Economic Models and Word Technical Reports

    Nov 1, 2025, 00:00

  • A4SLR: An Agentic Artificial Intelligence-Assisted Systematic Literature Review Framework to Augment Evidence Synthesis for Health Economics and Outcomes Research and Health Technology Assessment

    Nov 1, 2025, 00:00

  • Role of Generative Artificial Intelligence in Assisting Systematic Review Process in Health Research: A Systematic Review

    Nov 1, 2025, 00:00

  • Unravelling Public Preferences for the Use of Artificial Intelligence Mobile Health Applications in Australia

    Nov 1, 2025, 00:00

  • Author Reply

    Nov 1, 2025, 00:00

  • Are Generic Preference-Based Measures Valid for Use in Informal Carers? A Psychometric Investigation

    Nov 1, 2025, 00:00

  • Strong Preferences or Simplifying Heuristics? Using Internal Validity Tests and Latent Class Analysis to Better Understand Stated Preference Survey Results. A Case Example in Health Preferences Research

    Nov 1, 2025, 00:00

  • Use of Large Language Models to Extract Cost-Effectiveness Analysis Data: A Case Study

    Nov 1, 2025, 00:00

  • The “Artificial Intelligence Statistician”: Utilizing Generative Artificial Intelligence to Select an Appropriate Model and Execute Network Meta-Analyses

    Nov 1, 2025, 00:00

  • An Assessment of the Maturity of Cancer Survival Data Used in Economic Models for the National Institute for Health and Care Excellence’s Single Technology Appraisals

    Nov 1, 2025, 00:00

  • ELEVATE-GenAI: Reporting Guidelines for the Use of Large Language Models in Health Economics and Outcomes Research: An ISPOR Working Group Report

    Nov 1, 2025, 00:00

  • Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Trial-Based Economic Evaluation

    Nov 1, 2025, 00:00

  • Artificial Intelligence in Health Economics and Outcomes Research: Highlighting the Contributions of Early Career Researchers

    Nov 1, 2025, 00:00

  • Meditation and Mindfulness Practices as Supporting Tools to Mental Health Interventions in the Philippines

    Nov 1, 2025, 00:00

  • Table of Contents

    Nov 1, 2025, 00:00

  • Who Needs Real Data Anyway? Exploring the Use of Synthetic Data in Economic Evaluations of Health Interventions

    Nov 1, 2025, 00:00

  • How Similar Is Similar Enough? Assessment of Indirect Treatment Comparisons to Support Similarity for National Institute for Health and Care Excellence’s Cost Comparison Route

    Nov 1, 2025, 00:00

  • Editorial Board

    Oct 29, 2025, 10:30

  • Editorial Board

    Oct 6, 2025, 12:01

  • Assessing the Health-Related Quality of Life of Children With Asthma or Eczema by a Proxy: Does Assessment Perspective Matter?

    Oct 6, 2025, 08:52

  • Economic Evaluations of Treatment of Depressive Disorders in Adolescents: A Scoping Review

    Oct 1, 2025, 00:00

  • Measuring Aversion to Income-Related Health Inequality in Canada: An Equity-Efficiency Trade-Off Experiment

    Oct 1, 2025, 00:00

  • Cost-Effectiveness of Long-Chain Omega-3 Supplementation for the Secondary Prevention of Cardiovascular Disease in the United States

    Oct 1, 2025, 00:00

  • Head-to-Head Comparisons of the Distributional Characteristics and Measurement Properties of the 3-Level and 5-Level Versions of the EQ-5D-Y: A Systematic Review

    Oct 1, 2025, 00:00

  • Development of the County-Level Social Deprivation Index 2020 and Its Association With Health Outcomes in China

    Oct 1, 2025, 00:00

  • Economic Evaluation of the HEARTS Standardized Hypertension Treatment Program With Fixed-Dose Combination Pills in Chile Primary Care Clinics

    Oct 1, 2025, 00:00

  • Extending Multidimensional Thresholding to Include Categorical Attributes

    Oct 1, 2025, 00:00

  • Estimated True Out-of-Pocket Cost Changes From the Inflation Reduction Act on Medicare Part D Beneficiaries With Cancer

    Oct 1, 2025, 00:00

  • Provider Differences in Costs, Utilization, and Quality of Primary Care for Traumatic Brain Injury in the Military

    Oct 1, 2025, 00:00

  • Distributional Cost-Effectiveness Analysis and Health Technology Assessment at NICE

    Oct 1, 2025, 00:00

  • Cost per Opioid-Free Year: A Systematic Review and Summary Analysis

    Oct 1, 2025, 00:00

  • Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare

    Oct 1, 2025, 00:00

  • Meaningful Score Differences and Meaningful Score Regions of the Patient-Reported Outcomes Measurement Information System® Pediatric Asthma Impact Scale

    Oct 1, 2025, 00:00

  • Construction and Validation of a Risk Prediction Model for Prolonged Hospitalization of Very Premature Infants

    Oct 1, 2025, 00:00

  • Achieving Patient-Centered Value/Health Technology Assessment: Recommendations From a Multistakeholder eDelphi Panel

    Oct 1, 2025, 00:00

  • Rare Disease Policy in High-Income Countries: An Overview of Achievements, Challenges, and Solutions

    Oct 1, 2025, 00:00

  • Table of Contents

    Oct 1, 2025, 00:00

  • Using Machine Learning to Match Clients and Therapy Providers: Evaluating Clinical Quality and Cost of Care

    Sep 1, 2025, 00:00

  • Comparisons of Preferences Toward EQ-5D-Y-3L Health States Between Adult Own and Child Perspectives

    Sep 1, 2025, 00:00

  • Table of Contents

    Sep 1, 2025, 00:00

  • Quality of Care for Patients With Advanced Illness Scale: Development, Preference Elicitation, and Evaluation of Measurement Properties

    Sep 1, 2025, 00:00

  • Referencing Drug Prices of Other Countries May Not Sustainably Lower Prices in the United States: Lessons From Europe

    Sep 1, 2025, 00:00

  • Stability of Danish Population Health Preferences Over Time

    Sep 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7 (current)
  • 8
  • 9
  • 10
  • »